{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:48:50Z","timestamp":1788306530531,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T00:00:00Z","timestamp":1375747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Novartis Vaccines"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.vaccine.2013.08.006","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T14:00:22Z","timestamp":1376488822000},"page":"4968-4974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage"],"prefix":"10.1016","volume":"31","author":[{"given":"Giacomo","family":"Frosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Biolchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena Lo","family":"Sapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Rigat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lucidarme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia Monica","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duccio","family":"Medini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2013.08.006_bib0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0891-5520(05)70273-7","article-title":"Meningococcal vaccines","volume":"15","author":"Rosenstein","year":"2001","journal-title":"Infectious Disease Clinics of North America"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2013.08.006_bib0010","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0020","unstructured":"European Medicines Agency. Bexsero. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002333\/human_med_001614.jsp&mid=WC0b01ac058001d124 [accessed 11.03.13]."},{"key":"10.1016\/j.vaccine.2013.08.006_bib0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2958.2004.04423.x","article-title":"Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells","volume":"55","author":"Capecchi","year":"2005","journal-title":"Molecular Microbiology"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0030","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0035","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.01071-08","article-title":"Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37","volume":"77","author":"Seib","year":"2009","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0050","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/CVI.00039-07","article-title":"Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines","volume":"14","author":"Wedege","year":"2007","journal-title":"Clinical and vaccine immunology: CVI"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0060","series-title":"Handbook of meningococcal disease","first-page":"323","article-title":"Surrogates of protection","author":"Borrow","year":"2006"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0065","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0070","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0075","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States America"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0080","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms","volume":"95","author":"Maiden","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States America"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0085","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0090","series-title":"Sampling techniques","author":"Cochran","year":"1977"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0095","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA-Journal of the American Medical Association"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0105","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/CDLI.12.8.970-976.2005","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0110","series-title":"An introduction to statistical methods and data analysis","author":"Ott","year":"2010"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/bmj.309.6947.102","article-title":"Diagnostic tests 2: predictive values","volume":"309","author":"Altman","year":"1994","journal-title":"British Medical Journal"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0120","first-page":"295","article-title":"Practical tests of 2\u00d72 contingency tables","volume":"25","author":"Liddell","year":"1976","journal-title":"Journal of the Royal Statistical Society Series D (The Statistician)"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0125","doi-asserted-by":"crossref","first-page":"B67","DOI":"10.1016\/j.vaccine.2011.12.126","article-title":"The challenge of post-implementation surveillance for novel meningococcal vaccines","volume":"30","author":"Snape","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0130","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","article-title":"The disease burden of invasive meningococcal serogroup B disease in Canada","volume":"32","author":"Bettinger","year":"2012","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0135","series-title":"XVIIIth international pathogenic neisseria conference","article-title":"Retrospective analysis of Meningococcal Antigen Typing System (MATS) on serogroup B meningococcal isolates in Greece","author":"Tzanakaki","year":"2012"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0140","series-title":"XVIIIth international pathogenic Neisseria conference","article-title":"Strain coverage of a meningococcal mulitcomponent (4CMenB) vaccine in Spain","author":"Abad","year":"2012"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0145","series-title":"XVIIIth international pathogenic Neisseria conference","article-title":"Use of the Meningococcal Antigen Typing System (MATS) to assess the Australian meningococcal strain coverage with a multicomponent serogroup B vaccine","author":"Nissen","year":"2012"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0150","series-title":"XVIIIth international pathogenic Neisseria conference","article-title":"Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States","author":"Kim","year":"2012"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0155","series-title":"XVIIIth international pathogenic Neisseria conference","article-title":"MATS based coverage prediction for the 4CMenB vaccine on Neisseria meningitidis B (MenB) Brazilian invasive strains","author":"Lemos","year":"2012"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0160","series-title":"XVIIIth international pathogenic Neisseria conference","article-title":"Strain coverage of a multi-component meningococcus B vaccine in the Czech Republic and in Germany","author":"Claus","year":"2012"},{"key":"10.1016\/j.vaccine.2013.08.006_bib0165","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1128\/CVI.00202-12","article-title":"Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines","volume":"19","author":"Plikaytis","year":"2012","journal-title":"Clinical and Vaccine Immunology"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2020.06.048","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"record-id":"23684"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13010906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13010906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T23:29:12Z","timestamp":1596324552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13010906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":33,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0264410X13010906"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.08.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2013 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}